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Abstract
Background: Mice lacking glycosylated lysosomal membrane protein (Glmpgt/gt mice) have liver fibrosis as the
predominant phenotype due to chronic liver injury. The Glmpgt/gt mice grow and reproduce at the same rate as
their wild-type siblings. Life expectancy is around 18 months.
Methods: Wild-type and Glmpgt/gt mice were studied between 1 week and 18 months of age. Livers were analyzed
using histological, immunohistochemical, biochemical, and qPCR analyses.
Results: It was shown that Glmpgt/gt mice were not born with liver injury; however, it appeared shortly after birth as
indicated by excess collagen expression, deposition of fibrous collagen in the periportal areas, and increased levels of
hydroxyproline in Glmpgt/gt liver. Liver functional tests indicated a chronic, mild liver injury. Markers of inflammation,
fibrosis, apoptosis, and modulation of extracellular matrix increased from an early age, peaking around 4 months of age
and followed by attenuation of these signals. To compensate for loss of hepatocytes, the oval cell compartment was
activated, with the highest activity of the oval cells detected at 3 months of age, suggesting insufficient hepatocyte
proliferation in Glmpgt/gt mice around this age. Although constant proliferation of hepatocytes and oval cells
maintained adequate hepatic function in Glmpgt/gt mice, it also resulted in a higher frequency of liver tumors in older
animals.
Conclusions: The Glmpgt/gt mouse is proposed as a model for slowly progressing liver fibrosis and possibly as a model
for a yet undescribed human lysosomal disorder.
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Background
Mammalian liver plays a vital role in the maintenance of
body homeostasis. This homeostatic activity comprises
the supply of energy substances and a number of blood
components for which the liver is the only or major site
of synthesis, i.e., serum albumin [1]. In addition, the liver
removes a wide selection of potentially harmful sub-
stances arriving from the gut via the portal vein as well
as substances, which are needed for synthetic purposes.
Clearance from the circulatory system of various macro-
molecules and particles occurs by endocytosis, generally
leading to degradation of endocytosed substances in the
lysosomes followed by excretion or recycling of the
degradation products in synthetic pathways. The liver is
one of the most active metabolic organs of the body,
having a high turnover of its constituents. Degradation
of intracellular substances proceeds via the autophagic
pathway for which the lysosome is also the endpoint [2].
Proper functioning of the lysosomes is essential to the
homeostatic activity of hepatocytes and often also to their
survival [3]. A heterogeneous group of more than 50 con-
genital metabolic disorders characterized by the lack or
dysfunction of a protein within the endo-lysosomal pathway
has been described and categorized as lysosomal disorders
[4–11]. Most of these proteins are degradative enzymes or
membrane proteins [10, 11]. These lysosomal disorders
have widely varying phenotypes; however, symptoms are
often observed in tissues with low proliferation capacity,
such as the brain, or in cell types with a high substrate
turnover such as hepatocytes [7, 8, 12, 13]. A conse-
quence of lysosomal disorder is gradual accumulation
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of undegraded or unrecycled substances leading to increas-
ing pathogenic effects at the cellular and organ level even-
tually leading to systemic dysfunction [14, 15]. Depending
on the type and degree of such a lysosomal disorder, pa-
tients are faced with a shorter life expectancy [7, 8].
A frequent clinical manifestation in many lysosomal dis-
orders is liver fibrosis [9], a consistent result of almost every
type of prolonged or chronic liver injury [16]. Fibrogenesis
is characterized by hepatocyte apoptosis/necrosis and acti-
vation of Kupffer cells and hepatic stellate cells [16–19].
These events lead to release of a wide array of cytokines
(e.g., TGF-β, TNF-α, and PDGF), leading to infiltration of
leukocytes and further activation of stellate cells [17, 20,
21]. A state of inflammation results, often accompanied
with oxidative stress [17, 20, 21].
Fibrosis is a wound healing process during which the
balance between the extracellular matrix components is
shifted partly due to changes in expression of matrix genes,
such as collagen I, and partly due to changes in expression
of an array of matrix degrading enzymes and their inhibi-
tors, leading to accumulation of stiff, highly cross-linked
filamentous collagen structures [20, 22, 23]. If untreated,
liver fibrosis may proceed to liver cirrhosis, cancer, liver
failure, and eventually death [24]. Worldwide chronic
liver injury is one of the major causes of morbidity and
mortality [25].
The progression from chronic liver injury to liver fibrosis
and eventually cirrhosis depends on the etiology [17, 19].
Having access to animal models representing these different
pathologies is important in order to lay the foundation for
appropriate treatment strategies. Mouse models represent-
ing spontaneous liver fibrosis starting early in life but with
a slow progression are scarce [26, 27]. We recently reported
the successful generation of a mouse model lacking expres-
sion of the glycosylated lysosomal membrane protein
(GLMP) [28]. The physiological function of this protein is
unclarified, yet it appears to be essential to a healthy liver.
By the age of 6 months, the Glmpgt/gt mouse had developed
a marked liver fibrosis associated with hepatic cell death,
oxidative stress, active fibrogenesis, and activation of liver
progenitor cells [28].
The present study was undertaken to explore the age-
dependent development of liver fibrosis in Glmpgt/gt mice.
This report shows that development of liver fibrosis is initi-
ated shortly after birth in Glmpgt/gt mice and progresses to
a peak around 4 months of age. These mice are long-lived
but develop liver tumors at later stages in life. Expression of
inflammation markers and genes responsible for alteration
of the extracellular matrix increases from 2 weeks of age.
Activation of hepatic stellate cells and hepatic progenitor
cells is especially prominent around 3 to 4 months of age.
Further, expression of genes for inhibitors of cell cycle
progression is increased. At the age of 18 months, a major-
ity of the Glmpgt/gt mice had developed liver tumors. We
propose that the Glmpgt/gt mouse model may prove to be
very useful for studies of slowly progressing liver fibrosis




All animal experiments were reviewed and approved by
the Norwegian Animal Research Authority and performed
according to national laws and regulations. Generation of
wild-type (WT) and Glmpgt/gt mice has been described
[28]. The animals were housed in an approved animal
facility with access to standard rodent chow and water ad
libitum unless otherwise stated. Biological samples from
both males and females were collected at designated age-
points (newborn—18 months). Samples not immediately
processed or used for analyses were snap-frozen in liquid
N2 and stored at −80 °C until use.
Serum and hematological analysis
Blood was collected by cardiac puncture, coagulated at
room temperature before centrifugation at 1500g for
20 min. Serum was collected and immediately analyzed
for serum alanine transaminase [29], aspartate transaminase
(AST), γ-glutamyl-transferase, bile acid, bilirubin, and albu-
min concentrations at The Central Laboratory, Department
of Basic Sciences and Aquatic Medicine, Norwegian School
of Veterinary Science. Serum levels of TGF-β were assessed
using enzyme-linked immunosorbent assay (#MB100B,
R&D systems, Minneapolis, MN, USA) according to manu-
facturer’s procedure.
Blood was collected from 4.5-month-old male WT and
Glmpgt/gt mice by cardiac puncture into micro-vessel EDTA
tubes (Terumo Europe, Leuven, Belgium). Hematological
analyses were performed by The Central Laboratory, De-
partment of Basic Sciences and Aquatic Medicine, Norwe-
gian School of Veterinary Science.
Histochemistry
Mouse tissues were fixed in 10 % neutral buffered formalin
overnight, processed into paraffin blocks, and sectioned
into 4-μm-thick slices. Liver sections were stained with ei-
ther hematoxilin and eosin (H&E) or acid fuchsin orange G
(AFOG) according to standard techniques.
Immunohistochemistry
Formalin-fixed paraffin-embedded sections were deparaffi-
nized in xylene, rehydrated in a graded series of ethanol,
and demasked in a microwave oven for 24 min in Tris/
EDTA (TE) buffer (pH = 9.1). Antibodies for immunohisto-
chemistry were Rabbit monoclonal anti-Ki67 (1:500, SP6,
GTX16667, Cytotech ApS, Hellebæk, Denmark). Sections
were counterstained with hematoxylin, and the antigen-
antibody reaction was visualized with Dako EnVision horse
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radish peroxidase system using 3,3′-diaminobenzidine as
the chromogen (K4007, DAKO North America Inc.,
Camarillo, CA, USA).
Livers from four individual animals of each genotype and
age group were used for quantification of proliferating
hepatocytes. From each animal, two representative liver tis-
sue blocks were used for obtaining four randomly collected
slices including at least 1000 hepatocytes from each liver
(imaged with ×40 obj.). The total number of proliferative
hepatocytes, given as the sum of all positively Ki67 labeled
hepatocyte nuclei, and the semi-quantitative estimation of
the average number of hepatocyte nuclei included in a
magnification field were determined by counting.
Immunofluorescence
Immunofluorescence was performed as described previ-
ously [28]. Antibodies used for immunofluorescence were
Rat monoclonal anti-A6 (cell culture supernatant 1:25)
kindly provided by Dr. Valentina Factor [30] as primary
antibody and Alexa-Fluor-633 as secondary antibody
(Molecular Probes, Eugene, OR, USA), and sections were
counterstained with DAPI. Estimation of immunofluores-
cence intensity was graded in a semi-quantitative summary.
Transmission electron microscopy
Mice (n = 3, age 6 months) were subjected to perfusion
fixation using HEPES buffer (0.1 M, pH 7.2–7.4) with 4 %
formaldehyde and 2.5 % glutaraldehyde. Tissues were
collected, cut into blocks of 1 mm3, transferred to new
fixative solution, and kept at 4 °C overnight. The samples
were rinsed 2 × 10 min in 0.1 M sodium cacodylate buffer
prior to post-fixation (2 % OsO4 in 0.1 M sodium
cacodylate buffer) for 1 h, and rinsed 5 × 10 min in
distilled water before bulk staining with 1.5 % uranyl acetate
(CH3COO)2UO2·2H2O) [29] in distilled water for 30 min
in the dark. Fixed tissue samples were dehydrated in a
graded series of ethanol for 10 min each (70, 80, 90, 96 %),
4 × 15 min in 100 % ethanol and finally 2 × 10 min in pro-
pylene oxide. Following dehydration, tissue samples were
infiltrated with epoxy:propylene oxide (1:1) for 30–60 min
on a rotary shaker, evaporated overnight, and the following
day incubated 1 h in pure epoxy before embedding in plas-
tic capsules and polymerization at 60 °C. Five tissue blocks
were selected per individual mouse. Ultrathin sections were
obtained using a Leica Ultracut S microtome (Leica,
Wetzlar, Germany) with diamond knife and collected
on copper-coated grids before staining with lead citrate
for 20 s. All electron micrographs were obtained with a
CM100 transmission microscope (Philips, Amsterdam,
The Netherlands) at 80 kV.
Determination of Hydroxyproline
Briefly, frozen livers from WT and Glmpgt/gt mice were
ground into powder, hydrolyzed in 6 M hydrochloric acid
(HCl) at 100 °C o/n followed by centrifugation at 13,000g
for 10 min. Supernatants were diluted 1:2 with 4 M HCl.
Liver hydroxyproline contents were determined using
Hydroxyproline Assay kit (#QZBhypro2, QuickZyme Bio-
sciences, Leiden, The Netherlands), according to manufac-
turer’s protocol.
Gene expression analyses
RNA extractions from mouse liver were carried out accord-
ing to the manufacturer using RNeasy Plus kit (Qiagen,
Hilden, Germany). The expression of selected messenger
RNA (mRNA) transcripts (Additional file 1: Table S1) was
analyzed by quantitave PCR (qPCR) using a LightCycler
480 (Roche Diagnostics, Manheim, Germany) and LightCy-
cler® 480 SYBR Green I Master Mix (Roche Applied Sci-
ence). PCR efficiencies were experimentally determined for
each primer pair. Relative gene expression was calculated
using the ΔΔCt-method, with beta-actin and eukaryotic
translation elongation factor 2 as reference genes.
Statistical analysis
All results are expressed as mean ± s.e.m. All data were
analyzed using two-tailed t test (SigmaPlot™ , Systat Soft-
ware Inc, Chicago, IL, US) unless otherwise stated.
Results
Chronic liver inflammation is initiated shortly after birth in
Glmpgt/gt mice
As a background for evaluating the lack of GLMP expres-
sion on liver health, we measured the mRNA levels for
Glmp from birth till 9 months of age. Figure 1a shows a
rapid increase in Glmp expression within the first week of
life, reaching the adult levels by week 2. Next, livers from
wild-type (WT) and Glmpgt/gt mice were analyzed macro-
scopically and histologically. Figure 1b shows representative
liver macro images. No signs of liver injury were observed
in newborn mice (data not shown), nor did livers from
1 week old Glmpgt/gt mice show obvious signs of liver
injury. At 1 month of age, however, subcapsular bleeding
was observed (Fig. 1b). From the age of 3 months increas-
ing subcapsular contractions appeared, giving a nodular
appearance of Glmpgt/gt livers (Fig. 1b). By the age of
6 months, more distinct nodules were seen; however, at
9 months, the contracted liver surface appeared slightly
smoothened compared to 3 and 6 months old Glmpgt/gt
livers (Fig. 1b). Histological examination revealed infiltra-
tion of leukocytes as early as 1 week after birth in Glmpgt/gt
livers (Fig. 1c), followed by an increased number of infiltrat-
ing inflammatory cells as the animals grew older. A pro-
nounced distortion of the hepatic parenchymal architecture
was observed from 1 month of age (Fig. 1c). In addition,
the Glmpgt/gt livers were characterized by wide spread
extramedullar hematopoietic cells from the age of 1 week
to the age of 6 months (Fig. 1c). Very moderate amounts of
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such hematological precursors were only seen in 1 week
old WT livers as is typical for young individuals [31].
Expression of genes involved in inflammation and re-
cruitment of inflammatory cells in newborn Glmpgt/gt mice
was similar to that of WT confirming the observed absence
of liver injury in newborn Glmpgt/gt mice. In support of
histological analyses mRNA levels for the inflammation
marker S100 calcium-binding protein A8 (S100a8) and its
interacting partner S100a9, both ligands of the Receptor for
advanced glycation end-products (RAGE receptor) [32]
were markedly elevated in Glmpgt/gt livers from 1 week of
age (Fig. 2a,b). The expression of mRNA for Tnfa (Tumor
necrosis factor alpha) also increased but did not reach stat-
istical significance until 1 month of age in Glmpgt/gt livers
(Fig. 2c). A substantial increase in the expression levels of
these three genes was detected in Glmpgt/gt livers compared
to WT, reaching an apparent peak at 3.5–4.5 months of age
followed by reduced expression (Fig. 2a–c). The mRNA
expression of a sensor of damage-associated molecular
patterns, high-mobility group box 1 (HMGB1), also a ligand
of the RAGE receptor [33], showed a slower increase with
age peaking at 6 months of age and remaining elevated
throughout the observation period (Fig. 2d).
Histological and transmission electron microscopy
(TEM) analyses of other organs showed no abnormalities
in Glmpgt/gt mice (Additional file 2: Figure S1).
Reduced liver function in Glmpgt/gt mice
The apparent decrease in expression of inflammatory
marker genes after 3.5–4.5 months of age in Glmpgt/gt livers
were compared to liver functional analyses. In Glmpgt/gt
mice, modest but significantly elevated levels of serum
alanine transaminase [29] (Fig. 2e) and aspartate transamin-
ase (AST) were detected between 3.5 and 12 months of age
(Fig. 2f), indicating hepatocyte damage. The relative differ-
ences between genotypes were stable with age (Fig. 2e, f).
The serum bile acid levels were markedly elevated in
Glmpgt/gt mice compared to WTat all ages studied (Fig. 2g),
whereas serum albumin, a marker for hepatic function and




Fig. 1 Expression of GLMP in wild-type mice and analysis of the Glmpgt/gt phenotype. Wild-type (WT) and Glmpgt/gt mice were sacrificed at designated
time-points from newborn to 9 months of age, and their livers were extracted. a Expression of mRNA for GLMP at different time-points was measured
by qPCR. b Representative images of WT and Glmpgt/gt livers from selected time-points. Scale bar 1 cm. c Paraffin-embedded liver sections from WT and
Glmpgt/gt mice from age-matched mice, stained with hematoxylin and eosin, revealed extramedullar hematopoiesis (arrows) and infiltration of inflammatory
cells (arrowheads). Scale bar 100 μm
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Glmpgt/gt mice compared to WTat all ages studied (Fig. 2h).
Serum levels of γ-glutamyl-transferase and serum bilirubin
levels remained normal in Glmpgt/gt mice (data not shown).
Glmpgt/gt mice have anemia, thrombocytopenia, and
reduced levels of white blood cells
A complete blood analysis was performed on 4.5-month-
old WT and Glmpgt/gt mice. A decrease in concentration of
red blood cells (RBC), hemoglobin (HGB), and hematocrit
(HCT) and increase in the range of cellular sizes of eryth-
roid cells (RDW) in Glmpgt/gt mice were observed indicat-
ing anemia (Table 1). Furthermore, decreased platelet (PLT)
concentration in Glmpgt/gt mice was detected (Table 1) as
well as extended bleeding time (data not shown). The low
platelet count was in accordance with the decreased serum
levels of TGF-β in Glmpgt/gt mice, aged 3 weeks–15 months
(Additional file 3: Figure S2). In support of the observed
increase in infiltrating inflammatory cells in the Glmpgt/gt
liver, a significantly reduction in the levels of circulating
white blood cells (WBC) was observed in these mice com-
pared to WT mice (Table 1).
Liver fibrosis is initiated after birth in Glmpgt/gt mice
Staining of liver sections with AFOG showed no increase
in collagen staining in Glmpgt/gt livers compared to WT at
1 week of age (Fig. 3a). However, from 1 month of age,
excess collagen was clearly visible in the parenchyma of
Glmpgt/gt livers (Fig. 3a). Liver hydroxyproline levels were
quantified as a measure of excess collagen in Glmpgt/gt







Fig. 2 Expression of inflammatory markers and analysis of liver function. Relative mRNA expression of genes involved in inflammation and recruitment of
inflammatory cells was analyzed by qPCR and showed age-dependent changes in the expression of a S100a8, b S100a9, c Tnfa, and d Hmgb1 in Glmpgt/gt
liver (n= 4, *p< 0.05, **p< 0.01, ***p< 0.005 vs. WT). Values are presented as mean ± s.e.m. Blood serum was collected from wild-type (WT) and Glmpgt/gt
mice at 3.5, 6, and 12 months of age. Serum concentrations of e alanine transaminase [29], f aspartate transaminase (AST), g bile acids, and h albumin were
analyzed (n= 5–18, *p< 0.05, **p< 0.01, ***p< 0.005 vs. WT). Values are presented as mean ± s.e.m
Nesset et al. Fibrogenesis & Tissue Repair  (2016) 9:5 Page 5 of 13
levels of hydroxyproline did not differ from those of WT
mice, demonstrating that Glmpgt/gt mice were not born
with liver fibrosis. Elevated hydroxyproline contents were
detected in Glmpgt/gt livers from 2 weeks, indicating that
fibrogenesis had been initiated by this age (Fig. 3b). The
highest levels of hydroxyproline were detected in 4.5-
month-old Glmpgt/gt livers, reaching on average a threefold
increase compared to WT (Fig. 3b). In accordance with the
observed attenuation of inflammation in Glmpgt/gt livers
after 4.5 months (Figs. 1 and 2), the hydroxyproline levels
were reduced somewhat after this age (Fig. 3b).
Gene expression analyses of TGF-β (Fig. 4a), an inducer
of fibrogenesis, α-SMA (Fig. 4b), marker of activated
hepatic stellate cells, and proteins involved in matrix
remodeling collagen 1A1 (COL1A1), matrix metallopro
teinase-2 and 9 (MMP2, MMP9) and tissue inhibitor of
metalloproteinase-1 (TIMP1) (Fig. 4c–f ) revealed an in-
crease in expression peaking at 3.5–4.5 months of age
in Glmpgt/gt livers, where all markers were significantly
increased compared to WT. As with the inflammatory
markers (Fig. 2a–d) and collagen contents (Fig. 3a, b),
the relative differences between the genotypes was re-
duced after this age (Fig. 4).
Table 1 Blood analyses of 4.5 months old wild-type and
Glmpgt/gt mice
Wild-type (n = 10) Glmpgt/gt (n = 11)
RBC (×1012/L) 9.77 ± 0.08 9.17 ± 0.12***
HGB (g/dL) 14.01 ± 0.18 13.21 ± 0.18**
HCT (%) 45.5 ± 0.78 42.67 ± 0.90*
MCHC (g/dL) 30.85 ± 0.43 30.88 ± 0.37
MCV (μm3) 46.56 ± 0.70 46.68 ± 0.58
RDW (%) 13.78 ± 0.15 16.30 ± 0.27***
PLT (×1010/L) 84.68 ± 4.63 52.31 ± 6.92**
WBC (×109/L) 5.08 ± 0.44 2.98 ± 0.29**
Neutrophiles (×109/L) 0.65 ± 0.06 0.91 ± 0.14
Lymphocytes (×109/L) 3.86 ± 0.38 1.78 ± 0.18***
Eosinofilic (×109/L) 0.32 ± 0.05 0.13 ± 0.02**
LUC (×109/L) 0.14 ± 0.02 0.06 ± 0.02**
Monocytes N.D. N.D.
Basofilic N.D. N.D.
*p < 0.05; **p < 0.01, ***p < 0.005
RBC red blood cells, HGB hemoglobin, HCT hematocrit, MCHC mean
corpuscular hemoglobin concentration, MCV mean corpuscular volume,
RDW RBC distribution width, PLT platelets, WBC white blood cells, LUC large
unstained cells, N.D. not detected
A
B
Fig. 3 Determination of liver collagen expression and cross-linking. Representative images of paraffin-embedded liver sections from aged-matched
wild-type (WT) and Glmpgt/gt mice, stained with acid fuchsin orange G (blue) (a) revealed excess depositions of collagen in Glmpgt/gt liver parenchyma
from 1 month of age (arrows). Scale bar 100 μm. b Quantification of collagen in age-matched WT and Glmpgt/gt livers were determined by analyzing
liver hydroxyproline content (n = 3–4, *p < 0.05, **p < 0.01, ***p < 0.005 vs. WT). Values are presented as mean ± s.e.m
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Simultaneous loss and proliferation of hepatocytes in
Glmpgt/gt mice
An increased apoptotic activity has been demonstrated in
liver from Glmpgt/gt mice [28]. To explore the regenerative
capacity of WT and Glmpgt/gt livers, paraffin-embedded
liver sections were labeled for the proliferation marker
Ki67 [35]. Fig. 5a, b shows that the number of proliferating
cells is highly increased in 1-month-old Glmpgt/gt livers
compared to WT. A similar tendency, although not as
pronounced was observed in 3 and 6 months old mice
(Fig. 5b). At 9 months of age, the number of proliferating
hepatocytes was comparable between the genotypes
(Fig. 5a, b). Semi-quantitative estimation of the total hep-
atocyte number included in a microscopic field (×40 obj.)
showed comparable cell numbers at 1 month of age
(Fig. 5c). In Glmpgt/gt livers from 3- and 6-month-old
mice, the number of hepatocytes was lower compared to
WT due to enlarged size (Fig. 5c). However, at 9 months
of age, Glmpgt/gt mice appeared to have normalized the
number of hepatocytes (Fig. 5c).
To further investigate the proliferative status, the relative
expression of Cyclin D1 (CCND1), a key regulator of cell
cycle progression [36], was determined. Figure 5d shows an
increase in Ccnd1 expression at 1 month of age in Glmpgt/gt
livers compared to WT, followed by an expression peak at
3.5 months and a reduction in relative gene expression after
this age. The expression of Cyclin-dependent kinase inhibi-
tor 2A (Cdkn2a), an inhibitor of CCND1, the upregulation
of which promotes senescence and growth arrest [37], was
significantly upregulated in Glmpgt/gt livers compared to
WT at 1 week of age (Fig. 5e). Similar to the expression of
Ccnd1, and the other genes involved in inflammation and
fibrogenesis, the difference in relative Cdkn2a gene expres-




Fig. 4 Determination of liver fibrosis markers. Changes in mRNA expressions were assessed by qPCR. Analyses of age-matched mouse livers from
wild-type (WT) and Glmpgt/gt mice showed altered gene expression of a the fibrogenesis inducer Tgfb1, b the marker for activated hepatic stellate cells
αSma, c fibrillar collagen Col1a1, and genes involved in matrix remodeling d Timp1, e Mmp2, and f Mmp9 (n= 4, *p< 0.05, **p< 0.01, ***p< 0.005 vs. WT).
Values are presented as mean ± s.e.m
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age (Fig. 5e). At the peak age of 3.5 months, gene ex-
pression analyses of Cysteine-rich angiogenic inducer
61 (Cyr61), a marker for senescent cells, showed a signifi-
cant upregulation in Glmpgt/gt livers compared to WT
(Fig. 5f).
Oval cell expansion in Glmpgt/gt livers
The age-dependent activation of the hepatic oval cell com-
partment was studied by immunofluorescence staining for
the specific marker, A6 [30]. Figure 6 shows similar staining
in Glmpgt/gt and WT livers at 1 month of age. However, at
3 months, a strong increase in A6 staining was detected in
Glmpgt/gt livers, followed by a gradual decrease at 6 and
9 months of age, where the labeling is only slightly in-
creased in Glmpgt/gt livers compared to WT (Fig. 6).
Liver tumors develop in old Glmpgt/gt mice
Systematic evaluation of livers from Glmpgt/gt mice aged
between 12 and 18 months, revealed an increased fre-
quency of liver tumors compared to WT mice (Table 2).
Additional file 4: Figure S3 shows representative liver
macro images from 18 months old Glmpgt/gt and WT mice.
Hepatocellular tumors (Additional file 4: Figure S3A, B)
and hemangioma-like tumors with dilated vessels were de-
tected in the majority of Glmpgt/gt livers (Additional file 4:




Fig. 5 Hepatocyte proliferation and control of the cell cycle. Representative images of liver sections from aged-matched wild-type (WT) and Glmpgt/gt
mice (a) labeled for active Ki67 and counterstained with Mayer’s hematoxylin indicate cell proliferation (arrows). Scale bar 100 μm. b Quantification of
proliferating hepatocytes and c number of hepatocyte nuclei in aged-matched WT and Glmpgt/gt liver sections (n = 4, representing six random images
and at least 1000 hepatocytes from four individuals/genotype/age). Relative mRNA expression at designated age-points of the proliferation marker
d Ccnd1 and one of its inhibitor e Cdkn2a, and the expression of senescence marker f Cyr61 at 3.5 months were analyzed using qPCR in mouse livers
from WT and Glmpgt/gt mice (n = 4, *p < 0.05, **p < 0.01, ***p < 0.005 vs. WT). Values are presented as mean ± s.e.m
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body weight ratio was only slightly increased in 18 months
old Glmpgt/gt mice, and no significant differences were
detected for spleen/body weight ratio (data not shown).
The life expectancy of the Glmpgt/gt mice appeared to be
around 18 months, as the mortality rate of Glmpgt/gt mice
increased between 16 and 18 months of age (data not
shown). Liver functional tests, assessed by measuring serum
parameters, suggested that liver function in old Glmpgt/gt
mice was comparable to Glmpgt/gt mice of younger age
(Additional file 5: Figure S4 A, B, C, D). Similarly, total liver
collagen in Glmpgt/gt livers did not correlate with increasing
incidence of tumor growth (Additional file 6: Figure S5).
Discussion
In this report, the progression of chronic liver injury in
Glmpgt/gt mice across the expected life span is described.
In newborn Glmpgt/gt mice, no signs of liver injury were
detected, but chronic liver injury was initiated shortly after
birth. At 1 month of age signs of liver damage appeared in
the form of subcapsular bleeding, infiltration of inflamma-
tory cells and increased levels of hydroxyproline. Histo-
logical analyses detected increased deposition of fibrous
collagen in the periportal areas of Glmpgt/gt liver in ac-
cordance with the increased levels of hydroxyproline and
increased expression of α-smooth muscle actin (α-SMA)
due to activation of stellate cells, the major producers of
extracellular matrix components in both healthy and
fibrotic liver [38]. The increased presence of inflammatory
cells coincided with increased expression levels of mRNA
for inflammatory markers and cytokines, matrix modulat-
ing enzymes, and their inhibitors. A similar expression
pattern for Ccnd1 and Cdkn2a were observed. Further,
liver injury was reflected in the elevated serum transamin-
ase levels, mild anemia, increased hepatocyte proliferation,
and oval cell activation. Finally, a majority of Glmpgt/gt
mice developed liver cancers after the age of 12 months.
In wild-type mice Glmp expression increased rapidly
after birth, coinciding with the rapid growth of both liver
and the animal. In a recent report, we showed that the
liver/body weight ratio more than doubled in the first
2 weeks of life [39]. In the early phase of life, the liver
metabolism has to adapt to lactation and in this scenario,
the lack of GLMP presumably causes the chronic liver
injury leading to the observed fibrosis. In a previous
report, we showed increased apoptosis and oxidative stress
in Glmpgt/gt livers leading to hepatocyte loss [28]. Such a
loss may be compensated by proliferation of differentiated
hepatocytes or by oval cell proliferation and transdifferen-
tiation into hepatocytes. The former typically occurs after
mild or limited injuries to the liver by for instance carbon
tretrachloride (CCl4) [34]. However, in situations of per-
sistent or severe injury leading to insufficient hepatocyte
Fig. 6 Analysis of oval cell proliferation in Glmpgt/gt and wild-type mice. Livers from 1, 3, 6 and 9 months old wild type (WT) and Glmpgt/gt mice
were fixed and sectioned. Representative immunofluorescence images analyzing expression of the oval cell marker A6 (red). Liver sections were
counterstained with DAPI (blue). Scale bar: 50 μm. Semi-quantitative grading of A6-labeling intensities are indicated by + - signs, ranging from +
(control) to ++++ (most intense)
Table 2 Tumor frequencies in long-lived wild-type and Glmpgt/
gt mice
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proliferation, oval cells are mobilized to replace lost hepa-
tocytes or to complement an inadequate rate hepatocyte
of regeneration [40–43]. Increased hepatocyte prolifera-
tion and oval cell mobilization were observed in this study
up to the age of 6 months, indicating that lack of GLMP
resulted in persistent liver injury. Several rodent models
with chronic metabolic liver injuries are associated with
proliferation of oval cells in order to compensate for im-
paired hepatocyte proliferation [42–45]. After 6 months,
the oval cell activation declined, and the hepatocyte prolif-
eration appeared to be normalized in Glmpgt/gt livers
compared to WT. The liver injury and fibrosis, however,
had not been reversed as shown by the continued increase
in the levels of hydroxyproline and HMGB1. The ob-
served continued elevated levels of serum transaminases,
increased bile acids and lower serum albumin, often associ-
ated with chronic liver disease also supported the notion of
continued liver injury [46–48]. Proliferation of liver cells
was concomitant with the observed changes in gene ex-
pression of the regulator of cell cycle progression, CCND1
and its inhibitor CDKN2A, which increased shortly after
birth, reaching a peak around 3.5 months and followed by
a decline to normal levels at 9 months. The effect on cell
cycle regulation and increased expression of Cyr61 at
3.5 months indicated cell senescence and initiation of a
repair process [49]. The combined effect of these regula-
tors on cell proliferation may be to ensure that activated
stellate cells are silenced and damaged cells especially dam-
aged hepatocytes are removed. The increased expression of
Cyr61 indicated that regeneration of the liver is activated
and may be the reason for avoiding progression to severe
cirrhosis, liver failure, and early death [49]. Using micro-
array analyses of the Mdr2−/− mouse model for chronic
biliary injury [40]. Katzenellenbogen et al. showed that
DNA replication appeared normal in Mdr2−/− liver, while
cell division was inhibited, possibly as a protective mechan-
ism from uncontrolled proliferation [41]. At 9 months of
age, we detected comparable levels of Ki67 staining and
numbers of hepatocytes in Glmpgt/gt and WT livers, sug-
gesting establishment of a new balance between hepatocyte
death and replenishment. Activation of oval cells appeared
to be important for maintenance of liver function in
Glmpgt/gt mice. However, oval cells have also been shown to
contribute to the development of liver cancer [50, 51], a
common end-stage in chronic liver disease [19, 24, 52].
Even though liver functional tests indicated only a mild
liver injury and adequate hepatic function in old Glmpgt/gt
mice, the prolonged insult eventually promoted tumorigen-
esis in about 60 % of 18-month-old mice. A recent study
has questioned the true contribution of oval cell expansion
in the hepatocyte repopulation after liver injury [53]; how-
ever, our data showed that the oval cell compartment was
activated at the age where the highest expression of the cell
cycle inhibitor CDKN2A was detected [37] and that the
total number of hepatocytes normalized after oval cell acti-
vation. Further studies will be required to elucidate the role
of the oval cells in Glmpgt/gt liver.
In our first characterization of the Glmpgt/gt mice, we
reported accumulation of lipofuscin and iron in storage
vacuoles in Glmpgt/gt Kupffer cells [28]. Here, we show that
the Glmpgt/gt livers were exposed to chronic inflammation
right after birth. Further, we detected mild anemia in
Glmpgt/gt mice, consistent with anemia of inflammation [54,
55]. A study conducted by Nelson et al. [56] showed that
iron deposition specifically in Kupffer cells was associated
with metabolic liver injury. In a recent study, we have
demonstrated dysregulation of glucose and lipid metabol-
ism in Glmpgt/gt liver and isolated primary hepatocytes [39].
The absence of signs of liver injury in newborn Glmpgt/gt
mice suggests that GLMP may not be essential in mouse
prenatal life. At the mRNA level, Glmp expression has been
shown in mouse embryos [57], suggesting that GLMP
might have a role in a biological pathway not active until
birth. Dramatic changes in the hepatic gene expression
pattern take place right after birth in mice, switching from
primarily hematopoietic pathways to metabolic pathways
[57]. A disturbed lipid metabolism is a very likely generator
of reactive oxygen species (ROS), which are powerful in-
ducers of fibrosis [58]. Lipopolysaccharides (LPSs) leaked
from the intestine represent an additional contribution to
the development of liver fibrosis by causing inflammation
[59–61].
An interesting question is why fibrosis occurs in Glmpgt/
gt liver, and yet it appears to reach a new equilibrium after
6 months, albeit with a high risk of tumor development in
old animals. Based on the data presented here showing
that hepatocyte proliferation and oval cell proliferation
occur simultaneously, we hypothesize that four factors
may contribute to the observed fibrosis: the demand for
high activity in metabolic pathways after birth, increased
influx of LPS from the intestine, the demand for liver
growth to accompany the growth of the animal, and the
increased need to replace damaged hepatocytes. The high
demand for metabolic activity, especially with regard to
lipids, which occurs after birth, generates ROS and oxida-
tive stress in Glmpgt/gt hepatocytes due to their reduced
lipid metabolic capacity [39]. This impairs their prolifera-
tion potential and leads to apoptosis and influx of inflam-
matory cells from circulation [17, 19, 20]. Further, in the
first 4–5 months the liver has to increase its size to meet
the requirements of the growing animal. Simultaneously,
increased influx of LPS, secondary to chronic liver injury,
is carried via the portal circulation to liver [62–64]. Kupf-
fer cells can be activated by LPS [65] or through ingestion
of hepatocyte apoptotic bodies [66], leading to secre-
tion of pro-inflammatory and pro-fibrogenic cytokines
like TNF-α [66, 67] and TGF-β [29, 68]. These cytokines
are key activators of oval cells and hepatic stellate cells,
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respectively, in chronically injured liver [17, 20, 69]. In
addition, LPS can directly promote stellate cell activation
through toll-like receptor 4 (TLR4) [70]. During the growth
phase, expansion of the oval cell compartment is re-
quired in Glmpgt/gt liver in order to meet the demand
for replenishment of damaged hepatocytes and proliferation
for hyperplastic growth. However, around 6 months of age
the mice have reached their full body size and so has the
liver. When the demand for hyperplastic liver growth is no
longer relevant, the Glmpgt/gt liver appears less dependent
on oval cell expansion in maintaining adequate liver
function.
Conclusions
In summary, we have presented the entire liver disease
development in Glmpgt/gt mice, from initiation, progres-
sion, and compensation to tumor development over a life
span of 18 months. To our knowledge, this is the first in-
depth characterization of liver disease development in a
transgenic mouse model for a spontaneous, slowly pro-
gressing liver fibrosis. We show that liver injury is initiated
right after birth in Glmpgt/gt mice. The injury is mild, but
an imbalance between hepatocyte death and proliferation
activates the oval cell compartment by the age of 3 months.
A new balance between hepatocyte loss and replacement
appears to be reached by the age of 9 months; however, the
continuous proliferation eventually results in tumorigenesis
in Glmpgt/gt livers. Finally, based on our earlier data, we
suggest that metabolic liver injury may be the cause of the
liver disease in Glmpgt/gt mice and propose that this
Glmpgt/gt mouse model may become useful for studies of
slowly progressing liver fibrosis and possibly as a model for
a yet undescribed lysosomal disorder.
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